| Primary |
| Hypertension |
13.6% |
| Constipation |
10.2% |
| Convulsion Prophylaxis |
10.2% |
| Drug Use For Unknown Indication |
10.2% |
| Infection |
10.2% |
| Cerebral Infarction |
6.8% |
| Prophylaxis |
5.1% |
| Fluid Replacement |
3.4% |
| Gastric Ulcer |
3.4% |
| Gastritis |
3.4% |
| Hyperglycaemia |
3.4% |
| Infection Prophylaxis |
3.4% |
| Neurogenic Bladder |
3.4% |
| Nutritional Support |
3.4% |
| Pyrexia |
3.4% |
| Vitamin Supplementation |
3.4% |
| Hypercholesterolaemia |
1.7% |
| Blood Pressure Management |
0.8% |
| Myasthenia Gravis |
0.8% |
|
| Stevens-johnson Syndrome |
28.6% |
| Purpura |
21.4% |
| Inflammatory Bowel Disease |
14.3% |
| Liver Disorder |
14.3% |
| Ileus Paralytic |
7.1% |
| Renal Impairment |
7.1% |
| White Blood Cell Count Increased |
7.1% |
|
| Secondary |
| Hypertension |
26.0% |
| Sedation |
11.0% |
| Vitamin Supplementation |
9.1% |
| Pneumonia |
7.3% |
| Anaesthesia Procedure |
5.5% |
| Diuretic Therapy |
5.5% |
| Mineral Supplementation |
5.5% |
| Wound Complication |
3.7% |
| Cerebral Infarction |
3.2% |
| Product Used For Unknown Indication |
3.2% |
| Airway Burns |
2.7% |
| Constipation |
2.7% |
| Infection |
2.7% |
| Muscle Relaxant Therapy |
2.7% |
| Renal Hypertension |
2.7% |
| Convulsion Prophylaxis |
1.8% |
| Thermal Burn |
1.8% |
| Asthma |
0.9% |
| Cerebral Haemorrhage |
0.9% |
| Drug Use For Unknown Indication |
0.9% |
|
| Laryngeal Oedema |
42.1% |
| Toxic Epidermal Necrolysis |
15.8% |
| Liver Disorder |
7.9% |
| Malaise |
7.9% |
| Atrioventricular Block Complete |
5.3% |
| Interstitial Lung Disease |
5.3% |
| Papuloerythroderma Of Ofuji |
5.3% |
| Stevens-johnson Syndrome |
5.3% |
| Aortic Dissection |
2.6% |
| Phlebitis |
2.6% |
|
| Concomitant |
| Hypertension |
15.1% |
| Sedation |
9.1% |
| Fluid Replacement |
8.9% |
| Prophylaxis |
8.4% |
| Infection |
7.7% |
| Ureteral Stent Insertion |
6.2% |
| Ureteral Stent Removal |
6.2% |
| Infection Prophylaxis |
4.6% |
| Diuretic Therapy |
3.9% |
| Drug Use For Unknown Indication |
3.9% |
| Insomnia |
3.6% |
| Product Used For Unknown Indication |
3.3% |
| Pyrexia |
3.3% |
| Prophylaxis Against Graft Versus Host Disease |
3.1% |
| Anticoagulant Therapy |
2.6% |
| Electrolyte Substitution Therapy |
2.3% |
| Constipation |
2.2% |
| Acute Myocardial Infarction |
2.0% |
| Mineral Supplementation |
2.0% |
| Hypokalaemia |
1.7% |
|
| Respiratory Failure |
19.5% |
| Rhabdomyolysis |
8.6% |
| Staphylococcal Infection |
7.0% |
| Pneumonia Aspiration |
5.5% |
| Loss Of Consciousness |
4.7% |
| Viral Infection |
4.7% |
| White Blood Cell Count Increased |
4.7% |
| Delayed Recovery From Anaesthesia |
3.9% |
| Interstitial Lung Disease |
3.9% |
| Purpura |
3.9% |
| Septic Shock |
3.9% |
| Shock |
3.9% |
| Visual Field Defect |
3.9% |
| Cardiac Failure |
3.1% |
| Cerebral Haemorrhage |
3.1% |
| Platelet Count Decreased |
3.1% |
| Sepsis |
3.1% |
| Thrombotic Microangiopathy |
3.1% |
| Toxic Epidermal Necrolysis |
3.1% |
| Vasogenic Cerebral Oedema |
3.1% |
|
| Interacting |
|
| Urine Output Decreased |
100.0% |
|
